SciBase Holding AB (DE:5J3)
FRANKFURT:5J3
5J3 Stock Chart & Stats
€0.04
<€0.01(5.00%)
At close: 4:00 PM EST
€0.04
<€0.01(5.00%)
Day’s Range― - ―
52-Week Range€0.00 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€28.18M
Enterprise Value€129.46M
Total Cash (Recent Filing)€22.60M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding828,365,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€6.25M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthMulti-year revenue growth from 9.5M to 40.5M through 2025 signals durable commercial traction for the Nevisense platform and improving market adoption. Sustained top-line expansion supports scale economies, larger installed base and rising recurring procedure volumes that underpin longer-term revenue visibility.
High Gross MarginsA ~67% gross margin in 2025 reflects attractive product economics and favorable unit profitability for device and consumable sales. High gross margins provide room for targeted commercial investment and suggest that as procedure volumes increase, operating leverage can meaningfully improve operating income over time.
Recurring Consumable Revenue ModelDependence on disposable consumables and service contracts creates recurring, procedure-linked revenue that grows with installed base. This annuity-like component improves revenue predictability and margin resilience long term, enabling monetization of clinical adoption beyond one-time system sales.
Bears Say
Widening Operating LossesOperating losses expanded sharply in 2025 despite revenue gains, indicating persistent high operating costs or intensive commercial spend. Continued large EBIT deficits threaten the path to sustainable profitability and imply ongoing dependence on external funding unless costs are brought under control or revenue scale accelerates materially.
Severe Negative Cash FlowDeep and deteriorating operating and free cash flow in 2025 reflect structural burn that limits self-funding of growth. Persistent negative cash generation raises refinancing and dilution risk, constrains strategic flexibility, and makes the business vulnerable if capital markets tighten or fundraising terms become unfavorable.
Balance-sheet ErosionA sharp drop in equity and shrinking assets in 2025 compress the capital base despite low debt. This erosion reduces financial resilience and limits the company's ability to absorb setbacks, invest in commercialization, or pursue partnerships without dilutive financing, increasing strategic and solvency risk over the medium term.
SciBase Holding AB News
5J3 FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was €0.00 and its highest was €0.04 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is €28.18M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is May 07, 2026 which is in 28 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Mar 13, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.005.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 828,365,200 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -€0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in DE:5J3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally. Its product includes Nevisense and Nevisense Go, a point of care platform that addresses in the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company has a collaboration agreement with Advanced Dermatology and Cosmetic Surgery (ADCS) group. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―